Piper Sandler analyst Allison Bratzel initiates coverage on Incyte (NASDAQ:INCY) with a Overweight rating and announces Price Target of $100.
Incyte Corporation Announces Late Wednesday Phase 3 Data Showing Improvements In Facial And Total Body Repigmentation With Ruxolitinib Cream In Vitiligo Published In New England Journal Of Medicine
October 20, 12:34 AM
Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura™) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two
October 17, 1:59 PM
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ:CTIC) with an Outperform rating and a $13 price target. CTIC is a commercial-stage…
September 22, 11:14 AM
If history is any guide, there may be trouble ahead for shares of Incyte (NASDAQ:INCY). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.
September 15, 6:47 PM
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity…
August 26, 7:52 PM
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…